World Pharma AIRegister

All insights

Policy

FDA switches to 'Super Intelligence' wording for AI under new executive order

The change took effect on 16 November and the agency says it creates no new requirement for sponsors, applicants or manufacturers.

By World Pharma AI Editorial2 min read1 source

The US Food and Drug Administration began using the terms “Super Intelligence” and “SI” instead of “Artificial Intelligence” and “AI” in newly issued public-facing documents on 16 November 20261. The switch applies Executive Order 14434, Inaugurating the Era of Super Intelligence, which the President signed on 29 September 20261.

What the FDA has decided

The order tells executive departments and agencies to use the new wording, as far as the law permits, in official correspondence, public communications, websites, reports, policy documents and other non-statutory material1. It does not create a new class of technology. Section 3(a) defines “Super Intelligence” and “SI” as the technologies and systems already covered by the statutory definition of artificial intelligence in 15 U.S.C. 9401(3)1.

The FDA's notice sets out how the change will roll through its own material1:

  • new public-facing documents and communications use the new terms from 16 November, where applicable and legally permitted1
  • existing public-facing documents adopt the wording only at their next substantive revision, and web content changes on the regular maintenance cycle1
  • forms, electronic submission templates and databases are updated on their normal maintenance cycles1
  • where a statute or regulation says “artificial intelligence” or “AI”, the agency will keep quoting and citing those words as written1.

The agency also states that existing guidance documents, regulations, Federal Register notices and other documents it has already issued stay in effect as written1. Nothing already published is withdrawn or reopened by the change of vocabulary.

What it means for the market

For drug and biologic developers the FDA is explicit that the order binds executive departments and agencies only. It creates no new requirement for sponsors, applicants, manufacturers or anyone else submitting information to the agency, and that includes established names, proprietary names, trade names and labeling1.

The practical effect is on how sponsors read the agency. Regulatory affairs teams that track FDA output on AI in drug development, from discovery models to trial analytics and manufacturing software, will meet the new terms in fresh guidance and communications while older documents keep the familiar wording1. During the transition the same technology will therefore appear under two labels across FDA material1.

Because the definition is tied to the existing statutory meaning of artificial intelligence, the scope of what the FDA regulates does not change1. The notice gives no indication of any change to how the agency assesses AI-based methods in submissions. What it leaves open is how quickly the wording will spread through guidance revisions, since that depends on when each document next receives a substantive update1.

Caveats

The FDA notice covers terminology only, and it applies to the agency's own communications rather than to industry1. The agency's timetable for updating submission templates and databases is tied to normal maintenance cycles rather than to fixed dates1.

Sources

  1. FDA’s Use of “Super Intelligence” and “SI” Under Executive Order 14434 (opens in a new tab)FDA · fda.gov

This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.